Skip to main content

From Molecular Insights to Patient Stratification for Neurological and Psychiatric Disorders Proceedings of a Workshop (2022) / Chapter Skim
Currently Skimming:

2 Leveraging New Genetic and Neuroscience Technologies to Advance Therapeutic Development: Opportunities and Challenges
Pages 7-12

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 7...
... • Performing research at scale to ensure ancestral and content diversity in datasets and the generalizability of new insights will require building partnerships and collaborations across all sectors involved in the search for better treatments. NOTE: These points were made by Bill Martin, Janssen Research & Develop­ment; they are not intended to reflect a consensus among workshop participants.
Read the entire page →
From page 8...
... Martin.1 Rather, the field will need to embrace new technologies that facilitate a shift from categorical descriptions of disease based solely on clinical features to biologically defined patient populations based on neuro­ pathophysiological understanding, he said. This will require multimodal data from clinical, biological, and genetic studies, as well as new methodological frameworks and approaches to analyze and interpret these data to create novel insights.
Read the entire page →
From page 9...
... * Gastroenterology does not include inflammatory bowel disease.
Read the entire page →
From page 10...
... Additional public–private partnerships and consortia are also needed to increase the ancestral and content diversity of genomic information and take advantage of recent advances, for example, in the use of polygenic risk scores for patient stratification. "We need to systematically and intentionally expand the diversity 2  "Digital biomarkers are defined as objective, quantifiable physiological and behavioral data that are collected and measured by means of digital devices such as portables, wearables, implantables, or digestibles." Source: https://www.karger.com/Journal/guidelines/271954 (accessed January 31, 2022)
Read the entire page →
From page 11...
... Partnerships and data sharing among these entities can have a dramatic and positive impact on research advances and are essential in the crafting and implementation of regulatory policies and guidelines, he said. FIGURE 2-2  Types of biomarkers needed at all steps along the drug development pathway to assess pharmacodynamic response, predict risk of disease, predict efficacy of treatment, assess safety of a treatment, aid in diagnosis, and monitor the treatment response.
Read the entire page →

Key Terms

  • drug development
  • patient stratification
  • clinical development
  • advance therapeutic
  • clinical trials

  • patient populations
  • defined patient
  • clinical concept
  • janssen research
  • multimodal data

  • pathological hallmarks
  • disease based
  • biologically defined
  • categorical descriptions
  • require multimodal

  • treatment paradigms
  • clinical features
  • clinical studies
  • faster clinical
  • clinical trial

  • biologically based
  • ological frameworks
  • genetic studies
  • mechanisms closely
  • accelerate decision

  • based solely
  • bowel disease
  • alicia martin
  • trial disappointments
  • diverse datasets


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.